(S1 (S (NP (NP (NN Repression)) (PP (IN of) (NP (NP (NN fibroblast) (NN growth) (NN factor) (NN receptor) (CD 1)) (NN gene) (NN expression))) (PP (IN by) (NP (NN E2F4))) (PP (IN in) (NP (JJ skeletal) (NN muscle) (NNS cells))) (. .))))
(S1 (S (S (NP (NP (NP (NN Fibroblast) (NN growth) (NN factor) (NN receptor) (CD 1)) (PRN (-LRB- -LRB-) (NP (NN FGFR1)) (-RRB- -RRB-))) (NN gene) (NN expression)) (VP (VBZ is) (ADVP (ADVP (RB positively)) (CC and) (ADVP (RB negatively))) (VP (VBN regulated) (PP (IN during) (NP (NN muscle) (NN differentiation)))))) (. .)))
(S1 (S (S (NP (PRP We)) (ADVP (RB recently)) (VP (VBD reported) (SBAR (IN that) (S (NP (NN FGFR1) (NN gene) (NN expression)) (VP (VBD was) (VP (VBN up-regulated) (PP (IN by) (NP (NP (NN Sp) (NN transcription) (NNS factors)) (PP (IN in) (NP (VBG proliferating) (NNS myoblasts))))))))))) (. .)))
(S1 (S (S (ADVP (RB However)) (, ,) (NP (NP (DT the) (NN mechanism)) (PP (IN of) (NP (NP (NN down-regulation)) (PP (IN of) (NP (DT this) (NN gene))))) (PP (IN during) (NP (NN differentiation)))) (VP (VBZ is) (ADJP (JJ unknown)))) (. .)))
(S1 (S (S (NP (PRP We)) (VP (VBP have) (VP (VBN identified) (NP (DT the) (NN transcription) (NN factor) (NN E2F4)) (PP (IN as) (NP (NP (DT a) (JJ negative) (NN regulator)) (PP (IN of) (NP (NN FGFR1) (NN gene) (NN expression)))))))) (. .)))
(S1 (S (S (NP (NN Immunodetection) (NNS studies)) (VP (VBD revealed) (SBAR (IN that) (S (NP (JJ endogenous) (NN E2F1) (CC and) (NN E2F2) (NNS proteins)) (VP (VBD were) (ADJP (JJ cytoplasmic)) (PP (IN in) (NP (NP (NNS myoblasts)) (CC and) (NP (NNS myotubes)))) (, ,) (SBAR (IN whereas) (S (NP (NN E2F4)) (VP (VBD was) (ADJP (JJ abundant) (PP (IN in) (NP (NP (DT the) (NNS nuclei)) (PP (IN of) (NP (DT both)))))))))))))) (. .)))
(S1 (S (S (PP (IN Upon) (NP (NN overexpression))) (, ,) (S (NP (NN E2F4)) (VP (VBD repressed) (NP (NN FGFR1) (NN promoter) (NN activity)) (PP (IN in) (NP (DT a) (JJ dose-dependent) (NN manner))) (PP (IN in) (NP (NP (NNS myoblasts)) (CC and) (NP (NN Drosophila) (NN SL2) (NNS cells)))))) (, ,) (CC and) (S (NP (NP (NN mutation)) (PP (IN of) (NP (DT the) (NN E2F4) (NN binding) (NN site)))) (VP (VP (VBD increased) (NP (NN FGFR1) (NN promoter) (NN activity))) (CC and) (VP (VBD reduced) (NP (JJ E2F4-mediated) (NN repression)))))) (. .)))
(S1 (S (S (NP (NN Gel) (NN shift) (NNS assays)) (VP (VBD detected) (NP (NP (NN E2F4)) (VP (VBG binding) (PP (TO to) (NP (DT a) (JJ synthetic) (NN FGFR1) (NN E2F4) (NN binding) (NN site))))))) (CC and) (S (NP (NN chromatin) (NN immunoprecipitation) (NNS assays)) (VP (VBD detected) (NP (NP (NN E2F4) (NN binding)) (PP (TO to) (NP (DT the) (JJ endogenous) (NN FGFR1) (NN promoter))) (PP (IN in) (NP (NP (JJ proliferating) (NNS myoblasts)) (CC and) (NP (NNS myotubes))))))) (. .)))
(S1 (S (S (NP (DT The) (NNS results)) (VP (VBP indicate) (SBAR (IN that) (S (NP (NP (NN FGFR1) (NN promoter) (NN activity)) (PP (IN in) (NP (JJ skeletal) (NN muscle) (NNS cells)))) (VP (VBZ is) (VP (VBN repressed) (PP (IN by) (NP (NN E2F4))))))))) (. .)))
